vs

Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and KADANT INC (KAI). Click either name above to swap in a different company.

ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $271.6M, roughly 1.0× KADANT INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 10.2%, a 86.1% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs -0.0%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 6.7%).

Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.

Kadant Inc. is a company that was established in 1991, as a partly privately owned subsidiary of Thermo Electron, and partly publicly traded company, and was fully spun out and renamed Kadant in 2001. The company supports papermaking, paper recycling, wood processing, material handling, and other processing industries. Kadant is a multi-national corporation with operations in Asia, Europe, North America, and South America.

ACAD vs KAI — Head-to-Head

Bigger by revenue
ACAD
ACAD
1.0× larger
ACAD
$284.0M
$271.6M
KAI
Growing faster (revenue YoY)
ACAD
ACAD
+9.4% gap
ACAD
9.4%
-0.0%
KAI
Higher net margin
ACAD
ACAD
86.1% more per $
ACAD
96.3%
10.2%
KAI
Faster 2-yr revenue CAGR
ACAD
ACAD
Annualised
ACAD
17.5%
6.7%
KAI

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
ACAD
ACAD
KAI
KAI
Revenue
$284.0M
$271.6M
Net Profit
$273.6M
$27.7M
Gross Margin
90.8%
45.2%
Operating Margin
6.1%
15.7%
Net Margin
96.3%
10.2%
Revenue YoY
9.4%
-0.0%
Net Profit YoY
90.3%
-12.2%
EPS (diluted)
$1.61
$2.35

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACAD
ACAD
KAI
KAI
Q4 25
$284.0M
Q3 25
$278.6M
$271.6M
Q2 25
$264.6M
$255.3M
Q1 25
$244.3M
$239.2M
Q4 24
$259.6M
$258.0M
Q3 24
$250.4M
$271.6M
Q2 24
$242.0M
$274.8M
Q1 24
$205.8M
$249.0M
Net Profit
ACAD
ACAD
KAI
KAI
Q4 25
$273.6M
Q3 25
$71.8M
$27.7M
Q2 25
$26.7M
$26.2M
Q1 25
$19.0M
$24.1M
Q4 24
$143.7M
$24.0M
Q3 24
$32.8M
$31.6M
Q2 24
$33.4M
$31.3M
Q1 24
$16.6M
$24.7M
Gross Margin
ACAD
ACAD
KAI
KAI
Q4 25
90.8%
Q3 25
92.2%
45.2%
Q2 25
92.2%
45.9%
Q1 25
91.7%
46.1%
Q4 24
91.6%
43.4%
Q3 24
92.5%
44.7%
Q2 24
92.5%
44.4%
Q1 24
88.8%
44.6%
Operating Margin
ACAD
ACAD
KAI
KAI
Q4 25
6.1%
Q3 25
12.8%
15.7%
Q2 25
12.2%
15.4%
Q1 25
7.9%
14.9%
Q4 24
59.1%
14.3%
Q3 24
12.6%
18.0%
Q2 24
12.6%
17.6%
Q1 24
7.4%
14.8%
Net Margin
ACAD
ACAD
KAI
KAI
Q4 25
96.3%
Q3 25
25.8%
10.2%
Q2 25
10.1%
10.2%
Q1 25
7.8%
10.1%
Q4 24
55.4%
9.3%
Q3 24
13.1%
11.6%
Q2 24
13.8%
11.4%
Q1 24
8.0%
9.9%
EPS (diluted)
ACAD
ACAD
KAI
KAI
Q4 25
$1.61
Q3 25
$0.42
$2.35
Q2 25
$0.16
$2.22
Q1 25
$0.11
$2.04
Q4 24
$0.86
$2.04
Q3 24
$0.20
$2.68
Q2 24
$0.20
$2.66
Q1 24
$0.10
$2.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACAD
ACAD
KAI
KAI
Cash + ST InvestmentsLiquidity on hand
$177.7M
$124.5M
Total DebtLower is stronger
$254.6M
Stockholders' EquityBook value
$1.2B
$949.8M
Total Assets
$1.6B
$1.5B
Debt / EquityLower = less leverage
0.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACAD
ACAD
KAI
KAI
Q4 25
$177.7M
Q3 25
$258.0M
$124.5M
Q2 25
$253.6M
$95.3M
Q1 25
$217.7M
$91.7M
Q4 24
$319.6M
$94.7M
Q3 24
$155.1M
$88.4M
Q2 24
$177.1M
$73.8M
Q1 24
$204.7M
$81.4M
Total Debt
ACAD
ACAD
KAI
KAI
Q4 25
Q3 25
$254.6M
Q2 25
$245.7M
Q1 25
$273.5M
Q4 24
$285.2M
Q3 24
$323.2M
Q2 24
$342.0M
Q1 24
$306.8M
Stockholders' Equity
ACAD
ACAD
KAI
KAI
Q4 25
$1.2B
Q3 25
$917.3M
$949.8M
Q2 25
$822.4M
$926.0M
Q1 25
$765.2M
$876.0M
Q4 24
$732.8M
$847.1M
Q3 24
$577.2M
$851.7M
Q2 24
$516.7M
$807.7M
Q1 24
$464.0M
$782.7M
Total Assets
ACAD
ACAD
KAI
KAI
Q4 25
$1.6B
Q3 25
$1.3B
$1.5B
Q2 25
$1.2B
$1.5B
Q1 25
$1.1B
$1.4B
Q4 24
$1.2B
$1.4B
Q3 24
$976.9M
$1.5B
Q2 24
$914.1M
$1.5B
Q1 24
$855.1M
$1.4B
Debt / Equity
ACAD
ACAD
KAI
KAI
Q4 25
Q3 25
0.27×
Q2 25
0.27×
Q1 25
0.31×
Q4 24
0.34×
Q3 24
0.38×
Q2 24
0.42×
Q1 24
0.39×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACAD
ACAD
KAI
KAI
Operating Cash FlowLast quarter
$-48.7M
$47.3M
Free Cash FlowOCF − Capex
$44.1M
FCF MarginFCF / Revenue
16.2%
Capex IntensityCapex / Revenue
1.2%
Cash ConversionOCF / Net Profit
-0.18×
1.70×
TTM Free Cash FlowTrailing 4 quarters
$145.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACAD
ACAD
KAI
KAI
Q4 25
$-48.7M
Q3 25
$74.3M
$47.3M
Q2 25
$64.0M
$40.5M
Q1 25
$20.3M
$22.8M
Q4 24
$40.4M
$51.9M
Q3 24
$63.2M
$52.5M
Q2 24
$25.0M
$28.1M
Q1 24
$29.1M
$22.8M
Free Cash Flow
ACAD
ACAD
KAI
KAI
Q4 25
Q3 25
$73.9M
$44.1M
Q2 25
$36.5M
Q1 25
$19.0M
Q4 24
$46.3M
Q3 24
$63.2M
$48.3M
Q2 24
$23.1M
Q1 24
$16.6M
FCF Margin
ACAD
ACAD
KAI
KAI
Q4 25
Q3 25
26.5%
16.2%
Q2 25
14.3%
Q1 25
7.9%
Q4 24
17.9%
Q3 24
25.2%
17.8%
Q2 24
8.4%
Q1 24
6.7%
Capex Intensity
ACAD
ACAD
KAI
KAI
Q4 25
Q3 25
0.1%
1.2%
Q2 25
1.6%
Q1 25
1.6%
Q4 24
2.2%
Q3 24
0.0%
1.5%
Q2 24
1.8%
Q1 24
2.5%
Cash Conversion
ACAD
ACAD
KAI
KAI
Q4 25
-0.18×
Q3 25
1.03×
1.70×
Q2 25
2.40×
1.55×
Q1 25
1.07×
0.95×
Q4 24
0.28×
2.16×
Q3 24
1.93×
1.66×
Q2 24
0.75×
0.90×
Q1 24
1.76×
0.92×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACAD
ACAD

Nuplazid$174.4M61%
Daybue$109.6M39%

KAI
KAI

Flow Control$94.8M35%
Capital$83.2M31%
Material Handling Systems$70.3M26%
Transferred Over Time$17.1M6%
Other$6.1M2%

Related Comparisons